Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Neutral 0

AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill

📉 Stock price is currently $344.55 USD, representing a -1.17% drop in the last trading session and -2.44% decline over the past month.

📈 The stock has increased by 22.69% over the past year but received a low technical rating of 2 out of 10 from ChartMill.

🏅 Fundamental rating is assigned 5 out of 10, indicating excellent profitability paired with concerns regarding financial health.

📊 In Q4 results reported on February 2, 2026, the company beat EPS expectations by 9.56% and revenue expectations by 2.11%.

📈 Analysts project an average price target of $360.85 USD, suggesting a potential 4.73% price increase in the next year.

💰 The company offers a dividend yield of 2.89% with a current yearly dividend amount of $9.01.

📈 EPS growth is expected to be 4.51% and revenue growth 4.12% for the upcoming fiscal year.

💵 Non-GAAP Earnings per Share over the trailing twelve months were $21.85, reflecting a 10.24% increase from the prior year.

🧬 Amgen is a biotechnology company headquartered in Thousand Oaks, California, employing 31,500 full-time staff.

💊 Key marketed products include ENBREL, Repatha, Neulasta, and Parsabiv among others targeting unmet medical needs.

🏢 The company operates in the human therapeutics segment with a focus on high-value diseases.

🎯 CEO Robert A. Bradway leads the organization which discovered and develops human therapeutics.

💰 Market capitalization stands at $185.95 billion, classifying AMGN as a Large Cap stock.

Bullish Signals
  • AMGN reported an EPS of 5.29 and revenue of 9.87B on February 2, 2026, beating both EPS expectations by 9.56% and revenue expectations by 2.11%. The company's strong fundamentals were recognized with a 5/10 fundamental rating from ChartMill.
  • The stock has shown solid long-term growth with a price increase of 22.69% over the past year, outperforming 60.11% of all stocks in the market.
  • Analysts project positive future growth with an expected EPS increase of 4.51% and revenue growth of 4.12% for the next year.
  • The stock offers an attractive dividend yield of 2.89% with a yearly dividend amount of 9.01, providing regular income to shareholders.
  • Amgen operates in a high-growth sector focusing on human therapeutics for tough diseases with a large portfolio including ENBREL, Repatha, Otezla, and BLINCYTO.
  • The company is led by CEO Robert A. Bradway and employs 31,500 full-time employees, demonstrating substantial operational scale.
  • With a market capitalization of 185.95 billion USD, AMGN is classified as a large-cap stock, indicating stability in the biotechnology industry.
Risk Factors
  • The stock price is down -1.17% today and has decreased by -2.44% over the past month, indicating near-term weakness.
  • ChartMill assigns a poor technical rating of 2 / 10 to AMGN, signaling significant bearish sentiment from analysts.
  • Despite excellent profitability metrics, there are explicit concerns raised regarding the company's overall financial health.
  • Analyst price targets imply only a modest 4.73% expected increase in stock price over the next year based on current trading levels.
  • Revenue growth is forecast to be sluggish at just 4.12% for the coming year, suggesting limited expansion momentum.
  • The company operates with a large market capitalization of 185.95B USD, which may make it susceptible to high valuation risks if earnings miss.
Full Analysis
AMGen Inc. (NASDAQ: AMGN) is currently trading at $344.55, reflecting a -1.17% decline in the last session and a -2.44% decrease over the past month, though it has gained 22.69% annually. ChartMill assigns a technical rating of 2 out of 10 to the stock, indicating short-term volatility or weakness, while its fundamental rating stands at 5 out of 10. Fundamentally, the company scores well on profitability but faces concerns regarding its overall financial health. Despite these technical and rating metrics, AMGN is considered a medium performer in the broader market, outperforming 60.11% of all stocks on a yearly basis. On February 2, 2026, the company reported strong earnings with EPS of $5.29 and revenue of $9.87 billion, exceeding expectations by 9.56% and 2.11% respectively. Over the trailing twelve months, AMGen achieved a non-GAAP EPS of $21.85, marking a 10.24% increase from the previous year. Looking ahead, analysts forecast 43 price targets with an average of $360.85 USD, suggesting a potential 4.73% price increase in the next year. Revenue is projected to grow by 4.12% and EPS by 4.51% over the upcoming fiscal period. The company operates as a biotechnology firm headquartered in Thousand Oaks, California, employing 31,500 full-time staff focused on human therapeutics for unmet medical needs. Its product portfolio includes notable drugs such as ENBREL, Repatha, Otezla, and others marketed globally and in specific regions like the United States and Canada. AMGen has a market capitalization of $185.95 billion classifying it as a large-cap stock, with a CEO named Robert A. Bradway. Investors can note that AMGEN offers a dividend yield of 2.89% with an annual dividend amount of $9.01, though full profile details require registration on the platform.